head and neck cancer
The University of Michigan's MyHPVscore test uses Bio-Rad's Droplet Digital PCR assay technology to detect HPV DNA fragments that are released by tumor cells.
Cofactor Genomics Immunotherapy Response Test Nabs Medicare Coverage
The assay evaluates a patient's tumor immune profile against Cofactor's high-dimensional RNA-based Health Expression Models to predict a patient's therapy response.
Investigators published early case control data in a recent preprint showing remarkable sensitivity and are now considering their best options for further validation.
CMS Designates NavDx Test for HPV-Driven Cancer as ADLT
The test received Medicare coverage in 2023 for assessing molecular residual disease in patients with a history of HPV-driven head and neck cancer.
The firm hopes that Medicare coverage will facilitate patient access to the NavDx test and spur its inclusion in practice guidelines for head and neck cancer.